Granted Patent
B2
US 8,691,801 · App. 13/550,880 · Granted Apr 8, 2014
Use of manzamine compounds in anti-cancer therapeutic regimens
Inventors:
Esther A. Guzman (Fort Pierce, FL); Jacob D. Johnson (Silver Spring, MD); Amy E. Wright (Fort Pierce, FL)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.
Claims (1)
1. A method for inducing apoptosis in pancreatic cancer cells wherein said method comprises administering, to the cancer cells, an effective amount of manzamine Λ and TNF-related apoptosis-inducing ligand.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Sep 6, 2018
From: FLORIDA ATLANTIC UNIVERSITY
To: NATIONAL INSTITUES OF HEALTH - DIRECTOR DEITR
Reel/Frame 046800/0676 →
CONFIRMATORY LICENSE
Recorded Mar 14, 2014
From: FLORIDA ATLANTIC UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032449/0421 →
Continuity (3)
Provisional Application
60775435
· Feb 22, 2006